Regeneron Furnishes Preliminary Q4 2025 Financial Update at J.P. Morgan Conference
Summary
Regeneron Pharmaceuticals, Inc. furnished a corporate update presentation (via Ex. 99.1) at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation included preliminary financial information for the fourth quarter and full year 2025. The company expects a pre-tax acquired in-process research and development (IPR&D) charge of approximately $19 million for Q4 2025. This charge is anticipated to negatively impact GAAP and non-GAAP net income per diluted share for Q4 2025 by approximately $0.14.
Why It Matters
Investors should note the preliminary $19 million pre-tax IPR&D charge, which is expected to reduce Q4 2025 GAAP and non-GAAP net income per diluted share by approximately $0.14, as this provides an early signal on the company's upcoming financial results.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how REGN traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View REGN Charts on TradingViewAffiliate link
Key Quote
“non-GAAP net income per diluted share for the fourth quarter 2025 by approximately $0.14. Acquired IPR&D charges may include IPR&D.”
— From Item 2.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000872589
- Filing Date
- Monday, January 12, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- medium
- Sentiment
- positive